Equities researchers at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Friday. The firm set a "sell" rating on the stock.

Ayala Pharmaceuticals Stock Up 7.1 %

Shares of NASDAQ:ADXS traded up $0.10 during midday trading on Friday, reaching $1.51. The company's stock had a trading volume of 716 shares, compared to its average volume of 8,139. Ayala Pharmaceuticals has a 1 year low of $1.00 and a 1 year high of $10.80.

About Ayala Pharmaceuticals

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Further Reading

• Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows
• Europe Raises Interest Rates, Should the Fed Follow?

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.